Can China bring its own pipeline to the market?

Nature Biotechnology

Volumn 22, Issue 12, 2004, Pages 1497-1499

  Louët, Sabine ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

COSTS; DRUG PRODUCTS;

BIOTECH PLAYER; MONEY MEN; PHARMACEUTICAL INDUSTRY;

PIPELINES;

ANTIBODY; ARTEMISIN; ARTEMISIN DERIVATIVE; GENDICINE; GENE PRODUCT; GENERIC DRUG; UNCLASSIFIED DRUG; VACCINE;

BIOTECHNOLOGY; CHINA; CHINESE MEDICINE; CLINICAL TRIAL; COMPETITION; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; GENE THERAPY; GOVERNMENT; HUMAN; PATENT; PRIORITY JOURNAL; SHORT SURVEY; STANDARD;

BIOTECHNOLOGY; CHINA; DRUG APPROVAL; DRUG INDUSTRY; FINANCING, GOVERNMENT; MARKETING; PHARMACEUTICAL PREPARATIONS;

EID: 11144290579     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt1204-1497     Document Type: Short Survey

References (8)

1. General Biologic. "China Pipeline 2004" (General Biologic, Shanghai, China, 2004) (http://www.generalbiologic.com/).
2. Anscomb, A. Pharmaceutical outsourcing opportunities post launch. in Kalorama Information Market Intelligence (ed. Heffner, S.) (Kalorama Information, New York, 2004).
3. Basu, P. Nat. Biotechnol., 22, 263-265, 2004.
4. Pearson, S., Jia, H. & Kandachi, K. Nat. Biotechnol. 22, 3-4, 2004.
5. Jia, H. Nat. Biotechnol. 22, 368, 2004.
6. Liu, J.L. BioEntrepreneur 6 November 2003 (doi: 10.1038/bioent778).
7. Liu, J.L. Bioentrepreneur 23 October 2003 (doi:10.1038/bioent776).
8. McNeil, D.G. New York Times, May 14 (2004).